Drug profile · INN
omeprazole
ACIMAX TABLETS
omeprazole (ACIMAX TABLETS) is a potassium-transporting atpase inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — omeprazole
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 12
- Data quality
- 0.89
Quick answer
omeprazole (ACIMAX TABLETS) is a potassium-transporting atpase inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Potassium-transporting ATPase inhibitor
Primary target: Potassium-transporting ATPase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is omeprazole?
omeprazole (ACIMAX TABLETS) is a potassium-transporting atpase inhibitor. Associated with Alphapharm Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for omeprazole?
ACIMAX TABLETS is a marketed brand name for omeprazole. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of omeprazole?
omeprazole has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.